REGENXBIO Inc. (RGNX)
Stock Price:
$37.05 USD
1.40 (3.93%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
1.39B |
| Revenue (ttm) |
144.89M |
| Net Income (ttm) |
-91.47M |
| Shares Out |
37.41M |
| EPS (ttm) |
-2.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$37.05 |
| Previous Close |
$35.65 |
| Change ($) |
1.40 |
| Change (%) |
3.93% |
| Day's Open |
35.69 |
| Day's Range |
34.34 - 37.12 |
| Day's Volume |
117,976 |
| 52-Week Range |
20.03 - 54.97 |
More Stats
| Market Cap |
1.39B |
| Enterprise Value |
1.20B |
| Earnings Date (est) |
Mar 9, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.41M |
| Float |
33.67M |
| EPS (basic) |
-2.47 |
| EPS (diluted) |
-2.47 |
| FCF / Share |
-3.59 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.32M |
| Short Ratio |
10.17 |
| Short % of Float |
12.83% |
| Beta |
1.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.57 |
| PB Ratio |
3.21 |
| Revenue |
144.89M |
| Operating Income |
-105.91M |
| Net Income |
-91.47M |
| Free Cash Flow |
-134.05M |
| Net Cash |
181.83M |
| Net Cash / Share |
4.86 |
| Gross Margin |
-67.08% |
| Operating Margin |
-73.09% |
| Profit Margin |
-63.10% |
| FCF Margin |
-92.52% |
| ROA |
-12.60% |
| ROE |
-20.69% |
| ROIC |
-24.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
5 |
| Overweight |
1 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$57.50*
(55.20% upside)
Low
31.0
Current: $37.05
High
100.0
Target: 57.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 35.23 | 219 | 10.39 | 4.59 | 7.59 | 6.12 | 6.09 |
| Revenue Growth | -83.88% | 2002.42% | 126.48% | -39.52% | 23.99% | 0.54% | - |
| Gross Profit | 26.99 | 209 | 8.68 | 3.73 | 6.09 | 5.11 | 5.76 |
| Operating Income | -149 | 88.10 | -75.89 | -65.34 | -23.14 | -3.68 | -4.76 |
| Net Income | -94.73 | 99.94 | -73.17 | -62.97 | -22.81 | -4.00 | -5.39 |
| Shares Outstanding | 36.69 | 33.43 | 29.88 | 26.41 | 9.17 | 2.64 | 2.32 |
| Earnings Per Share | -2.58 | 2.73 | -2.45 | -2.38 | -2.59 | -1.82 | -2.50 |
| Operating Cash Flow | -108 | 105 | -57.99 | -48.56 | -22.52 | -2.40 | -3.01 |
| Capital Expenditures | -11.72 | -13.28 | -7.16 | -8.15 | -0.52 | - | - |
| Free Cash Flow | -119 | 91.37 | -65.15 | -56.71 | -23.04 | -2.40 | -3.01 |
| Cash & Equivalents | 298 | 321 | 161 | 89.78 | 114 | 1.12 | 1.12 |
| Total Debt | 11.30 | 5.85 | - | - | - | 2.40 | - |
| Net Cash / Debt | 286 | 315 | 161 | 89.78 | 114 | -1.28 | 1.12 |
| Assets | 498 | 544 | 199 | 173 | 221 | 3.49 | 2.51 |
| Liabilities | 47.71 | 34.97 | 15.65 | 11.00 | 4.57 | 9.19 | 4.65 |
| Book Value | 450 | 509 | 183 | 162 | 217 | -18.29 | -13.92 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
REGENXBIO Inc. |
| Country |
United States |
| Employees |
257 |
| CEO |
Kenneth T. Mills |
Stock Information
| Ticker Symbol |
RGNX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RGNX |
| IPO Date |
September 17, 2015 |
Description
REGENXBIO, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.